163 related articles for article (PubMed ID: 22430977)
1. Characterization of UC781-tenofovir combination gel products for HIV-1 infection prevention in an ex vivo ectocervical model.
Cost M; Dezzutti CS; Clark MR; Friend DR; Akil A; Rohan LC
Antimicrob Agents Chemother; 2012 Jun; 56(6):3058-66. PubMed ID: 22430977
[TBL] [Abstract][Full Text] [Related]
2. Design of tenofovir-UC781 combination microbicide vaginal gels.
Kiser PF; Mahalingam A; Fabian J; Smith E; Damian FR; Peters JJ; Katz DF; Elgendy H; Clark MR; Friend DR
J Pharm Sci; 2012 May; 101(5):1852-64. PubMed ID: 22359356
[TBL] [Abstract][Full Text] [Related]
3. In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide.
Rohan LC; Moncla BJ; Kunjara Na Ayudhya RP; Cost M; Huang Y; Gai F; Billitto N; Lynam JD; Pryke K; Graebing P; Hopkins N; Rooney JF; Friend D; Dezzutti CS
PLoS One; 2010 Feb; 5(2):e9310. PubMed ID: 20174579
[TBL] [Abstract][Full Text] [Related]
4. Development of HIV-1 rectal-specific microbicides and colonic tissue evaluation.
Dezzutti CS; Russo J; Wang L; Abebe KZ; Li J; Friend DR; McGowan IM; Rohan LC
PLoS One; 2014; 9(7):e102585. PubMed ID: 25025306
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of tenofovir/IQP-0528 combination gels - a dual compartment microbicide for HIV-1 prevention.
Dezzutti CS; Shetler C; Mahalingam A; Ugaonkar SR; Gwozdz G; Buckheit KW; Buckheit RW
Antiviral Res; 2012 Nov; 96(2):221-5. PubMed ID: 22940075
[TBL] [Abstract][Full Text] [Related]
6. Does tenofovir gel or do other microbicide products affect detection of biomarkers of semen exposure in vitro?
Snead MC; Kourtis AP; Melendez JH; Black CM; Mauck CK; Penman-Aguilar A; Chaney DM; Gallo MF; Jamieson DJ; Macaluso M; Doncel GF
Contraception; 2014 Aug; 90(2):136-41. PubMed ID: 24746557
[TBL] [Abstract][Full Text] [Related]
7. Characterization of cyclodextrin inclusion complexes of the anti-HIV non-nucleoside reverse transcriptase inhibitor UC781.
Yang H; Parniak MA; Isaacs CE; Hillier SL; Rohan LC
AAPS J; 2008 Dec; 10(4):606-13. PubMed ID: 19089644
[TBL] [Abstract][Full Text] [Related]
8. UC781 microbicide gel retains anti-HIV activity in cervicovaginal lavage fluids collected following twice-daily vaginal application.
Haaland RE; Evans-Strickfaden T; Holder A; Pau CP; McNicholl JM; Chaikummao S; Chonwattana W; Hart CE
Antimicrob Agents Chemother; 2012 Jul; 56(7):3592-6. PubMed ID: 22508307
[TBL] [Abstract][Full Text] [Related]
9. Dose-response relationship between tissue concentrations of UC781 and explant infectibility with HIV type 1 in the RMP-01 rectal safety study.
Richardson-Harman N; Mauck C; McGowan I; Anton P
AIDS Res Hum Retroviruses; 2012 Nov; 28(11):1422-33. PubMed ID: 22900504
[TBL] [Abstract][Full Text] [Related]
10. Rectal microbicide development.
McGowan I
Curr Opin HIV AIDS; 2012 Nov; 7(6):526-33. PubMed ID: 23032732
[TBL] [Abstract][Full Text] [Related]
11. Development of a combination microbicide gel formulation containing IQP-0528 and tenofovir for the prevention of HIV infection.
Ham AS; Ugaonkar SR; Shi L; Buckheit KW; Lakougna H; Nagaraja U; Gwozdz G; Goldman L; Kiser PF; Buckheit RW
J Pharm Sci; 2012 Apr; 101(4):1423-35. PubMed ID: 22227864
[TBL] [Abstract][Full Text] [Related]
12. First phase 1 double-blind, placebo-controlled, randomized rectal microbicide trial using UC781 gel with a novel index of ex vivo efficacy.
Anton PA; Saunders T; Elliott J; Khanukhova E; Dennis R; Adler A; Cortina G; Tanner K; Boscardin J; Cumberland WG; Zhou Y; Ventuneac A; Carballo-Diéguez A; Rabe L; McCormick T; Gabelnick H; Mauck C; McGowan I
PLoS One; 2011; 6(9):e23243. PubMed ID: 21969851
[TBL] [Abstract][Full Text] [Related]
13. Preclinical safety assessments of UC781 anti-human immunodeficiency virus topical microbicide formulations.
Patton DL; Sweeney YT; Balkus JE; Rohan LC; Moncla BJ; Parniak MA; Hillier SL
Antimicrob Agents Chemother; 2007 May; 51(5):1608-15. PubMed ID: 17353240
[TBL] [Abstract][Full Text] [Related]
14. Increased Dapivirine tissue accumulation through vaginal film codelivery of dapivirine and Tenofovir.
Akil A; Devlin B; Cost M; Rohan LC
Mol Pharm; 2014 May; 11(5):1533-41. PubMed ID: 24693866
[TBL] [Abstract][Full Text] [Related]
15. The safety, persistence, and acceptability of an antiretroviral microbicide candidate UC781.
Bunge K; Macio I; Meyn L; Noguchi L; Parniak MA; Schwartz JL; Moncla B; Hillier S
J Acquir Immune Defic Syndr; 2012 Aug; 60(4):337-43. PubMed ID: 22495787
[TBL] [Abstract][Full Text] [Related]
16. Drug synergy of tenofovir and nanoparticle-based antiretrovirals for HIV prophylaxis.
Chaowanachan T; Krogstad E; Ball C; Woodrow KA
PLoS One; 2013; 8(4):e61416. PubMed ID: 23630586
[TBL] [Abstract][Full Text] [Related]
17. Models for predicting effective HIV chemoprevention in women.
Nicol MR; Emerson CW; Prince HM; Nelson JA; Fedoriw Y; Sykes C; Geller EJ; Patterson KB; Cohen MS; Kashuba AD
J Acquir Immune Defic Syndr; 2015 Apr; 68(4):369-76. PubMed ID: 25501616
[TBL] [Abstract][Full Text] [Related]
18. Genital Tenofovir Concentrations Correlate With Protection Against HIV Infection in the CAPRISA 004 Trial: Importance of Adherence for Microbicide Effectiveness.
Kashuba AD; Gengiah TN; Werner L; Yang KH; White NR; Karim QA; Abdool Karim SS
J Acquir Immune Defic Syndr; 2015 Jul; 69(3):264-9. PubMed ID: 26181703
[TBL] [Abstract][Full Text] [Related]
19. Efficacy, pharmacokinetics, and in vivo antiviral activity of UC781, a highly potent, orally bioavailable nonnucleoside reverse transcriptase inhibitor of HIV type 1.
Buckheit RW; Hollingshead M; Stinson S; Fliakas-Boltz V; Pallansch LA; Roberson J; Decker W; Elder C; Borgel S; Bonomi C; Shores R; Siford T; Malspeis L; Bader JP
AIDS Res Hum Retroviruses; 1997 Jun; 13(9):789-96. PubMed ID: 9171223
[TBL] [Abstract][Full Text] [Related]
20. In vitro evaluation of viability, integrity, and inflammation in genital epithelia upon exposure to pharmaceutical excipients and candidate microbicides.
Gali Y; Delezay O; Brouwers J; Addad N; Augustijns P; Bourlet T; Hamzeh-Cognasse H; Ariën KK; Pozzetto B; Vanham G
Antimicrob Agents Chemother; 2010 Dec; 54(12):5105-14. PubMed ID: 20921308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
